PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells.

Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Dinoprostone/*metabolism ; Endothelial Cells/*metabolism ; Lymphangiogenesis/*physiology ; Mammary Neoplasms, Experimental/*pathology ; Receptors, Prostaglandin E, EP4 Subtype/*metabolism; Animals ; Blotting, Western ; Cell Line, Tumor ; Endothelial Cells/pathology ; Enzyme-Linked Immunosorbent Assay ; Female ; Mice ; Mice, Nude ; Rats ; Real-Time Polymerase Chain Reaction

Background: Lymphatic metastasis, facilitated by lymphangiogenesis is a common occurrence in breast cancer, the molecular mechanisms remaining incompletely understood. We had earlier shown that cyclooxygenase (COX)-2 expression by human or murine breast cancer cells promoted lymphangiogenesis and lymphatic metastasis by upregulating VEGF-C/D production by tumor cells or tumor-associated macrophages primarily due to activation of the prostaglandin receptor EP4 by endogenous PGE2. It is not clear whether tumor or host-derived PGE2 has any direct effect on lymphangiogenesis, and if so, whether EP4 receptors on lymphatic endothelial cells (LEC) play any role.
Methods: Here, we address these questions employing in vitro studies with a COX-2-expressing and VEGF-C/D-producing murine breast cancer cell line C3L5 and a rat mesenteric (RM) LEC line and in vivo studies in nude mice.
Results: RMLEC responded to PGE2, an EP4 agonist PGE1OH, or C3L5 cell-conditioned media (C3L5-CM) by increased proliferation, migration and accelerated tube formation on growth factor reduced Matrigel. Native tube formation by RMLEC on Matrigel was abrogated in the presence of a selective COX-2 inhibitor or an EP4 antagonist. Addition of PGE2 or EP4 agonist, or C3L5-CM individually in the presence of COX-2 inhibitor, or EP4 antagonist, restored tube formation, reinforcing the role of EP4 on RMLEC in tubulogenesis. These results were partially duplicated with a human dermal LEC (HMVEC-dLyAd) and a COX-2 expressing human breast cancer cell line MDA-MB-231. Knocking down EP4 with shRNA in RMLEC abrogated their tube forming capacity on Matrigel in the absence or presence of PGE2, EP4 agonist, or C3L5-CM. RMLEC tubulogenesis following EP4 activation by agonist treatment was dependent on PI3K/Akt and Erk signaling pathways and VEGFR-3 stimulation. Finally in a directed in vivo lymphangiogenesis assay (DIVLA) we demonstrated the lymphangiogenic as well as angiogenic capacity of PGE2 and EP4 agonist in vivo.
Discussion/conclusions: These results demonstrate the roles of tumor as well as host-derived PGE2 in inducing lymphangiogenesis, at least in part, by activating EP4 and VEGFR-3 on LEC. EP4 being a common target on both tumor and host cells contributing to tumor-associated lymphangiogenesis reaffirms the therapeutic value of EP4 antagonists in the intervention of lymphatic metastasis in breast cancer.

Lymphat Res Biol. 2006;4(3):119-42. (PMID: 17034293)
Lab Invest. 2012 Aug;92(8):1115-28. (PMID: 22641101)
J Clin Invest. 2014 Sep;124(9):3901-12. (PMID: 25133426)
Cancer Cell. 2002 Apr;1(3):219-27. (PMID: 12086857)
Cell. 2010 Mar 19;140(6):883-99. (PMID: 20303878)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
PLoS One. 2012;7(4):e35094. (PMID: 22545097)
J Thorac Cardiovasc Surg. 1996 Sep;112(3):623-30. (PMID: 8800148)
BMJ. 2006 Jun 3;332(7553):1302-8. (PMID: 16740558)
N Engl J Med. 2004 Oct 21;351(17):1709-11. (PMID: 15470192)
Pathophysiology. 2010 Sep;17(4):229-51. (PMID: 20036110)
Int J Oral Sci. 2010 Mar;2(1):5-14. (PMID: 20690413)
Int J Cancer. 2004 Jan 20;108(3):384-9. (PMID: 14648704)
Genes Cancer. 2011 Dec;2(12):1146-58. (PMID: 22866206)
Mol Cancer. 2015 Feb 10;14:35. (PMID: 25744065)
Cancer Lett. 2015 Mar 28;358(2):200-9. (PMID: 25543087)
Blood. 2011 Nov 10;118(19):5355-64. (PMID: 21926356)
Exp Cell Res. 2003 Oct 1;289(2):265-74. (PMID: 14499627)
Stem Cells. 2016 Sep;34(9):2290-305. (PMID: 27301070)
Am J Surg. 2002 Dec;184(6):492-8; discussion 498. (PMID: 12488144)
Int J Gynecol Cancer. 2011 Feb;21(2):245-50. (PMID: 21721192)
Int J Cancer. 1997 Nov 4;73(3):371-80. (PMID: 9359485)
PLoS One. 2012;7(7):e41178. (PMID: 22844439)
JAMA. 2006 Oct 4;296(13):1653-6. (PMID: 16968830)
Br J Cancer. 2006 Apr 24;94(8):1154-63. (PMID: 16570043)
Lab Invest. 2013 Jul;93(7):779-91. (PMID: 23711825)
Cancer Sci. 2014 Sep;105(9):1142-51. (PMID: 24981602)
Oncogene. 1999 Dec 20;18(55):7908-16. (PMID: 10630643)
Hum Pathol. 2000 May;31(5):578-83. (PMID: 10836297)
Int J Cancer. 2001 Aug 15;93(4):497-506. (PMID: 11477553)
Cell Immunol. 1986 Apr 15;99(1):108-18. (PMID: 2944621)
Mol Pharmacol. 2005 Jul;68(1):251-9. (PMID: 15855407)
Mol Cancer Res. 2015 Jun;13(6):1022-33. (PMID: 25733698)
Ann Surg Oncol. 2002 Mar;9(2):192-6. (PMID: 11888878)
BMC Cancer. 2011 Jun 02;11:216. (PMID: 21635742)
Int J Cancer. 1993 Jun 19;54(4):677-84. (PMID: 8514459)
Cancer Immunol Immunother. 2011 Nov;60(11):1577-86. (PMID: 21681369)
J Biol Chem. 2008 Apr 25;283(17):11155-63. (PMID: 18319253)
Cancer Metastasis Rev. 2007 Dec;26(3-4):525-34. (PMID: 17763971)
Int J Gynecol Cancer. 2009 Jan;19(1):21-6. (PMID: 19258936)
Cancer Sci. 2010 Sep;101(9):2026-32. (PMID: 20608938)

Keywords: Angiognesis; Breast cancer; Cyclooxygenase (COX)-2; Directed in vivo lymphangiogenesis assay (DIVLA); EP4 antagonist; EP4 receptors; Lymphangiogenesis; Lymphatic endothelial cells; Metastasis; PGE2

0 (Receptors, Prostaglandin E, EP4 Subtype)
K7Q1JQR04M (Dinoprostone)

Date Created: 20170107 Date Completed: 20171025 Latest Revision: 20220410

20221213

PMC5217626

10.1186/s12885-016-3018-2

28056899